Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02950012 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population

A Phase 2 study of Bloating, sponsored by BIO-CAT Microbials.

Completed
Registry status
Phase 2
Development phase
100
Enrollment target
3
Study locations

NCT02950012 is a Phase 2 study of Bloating that has completed, run by BIO-CAT Microbials. The registered enrollment target is 100 participants, above the 83-participant average among 5 other Bloating trials with a reported enrollment target (20% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02950012, a Phase 2 study of Bloating, has completed, sponsored by BIO-CAT Microbials.

COMPLETED
Registry status
Phase 2
Development phase
100 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in otherwise healthy adults.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT OPTI-BIOME™ Bacillus subtilis MB40

Study Locations (3)

California

  • KGK Clinical Trials Center - Foothill Ranch

Florida

  • KGK Clinical Trials Center - Orlando

Ontario

  • KGK Synergize Inc. - London

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-10
Est. Completion 2017-02
Phase Phase 2

Sponsor

BIO-CAT Microbials

3 total trials

What the Registry Record Tells You About NCT02950012

The ClinicalTrials.gov registry entry for NCT02950012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 5 other Bloating trials with a reported enrollment target (20% higher). The listed sponsor is BIO-CAT Microbials, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bloating appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02950012 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Ontario.

Frequently Asked Questions

What is clinical trial NCT02950012 about?

NCT02950012 is a clinical study titled "A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population". The purpose of this study is to investigate the effects of OPTI-BIOME™ (Bacillus subtilis MB40), a probiotic supplement, on bloating, gas and abdominal discomfort symptoms in otherwise healthy adults.

What is the current status of trial NCT02950012?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2016-10. Estimated completion is 2017-02.

What conditions does trial NCT02950012 study?

This clinical trial studies the following conditions: Bloating.

What interventions are being tested in trial NCT02950012?

The interventions under investigation include: Placebo (OTHER), OPTI-BIOME™ Bacillus subtilis MB40 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02950012?

This trial is sponsored by BIO-CAT Microbials, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02950012 being conducted?

This trial has 3 study locations across California, Florida, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bloating

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.